JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beaver, W. T.
Right arrow Articles by Houde, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beaver, W. T.
Right arrow Articles by Houde, R. W.

Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone

WT Beaver, SL Wallenstein, A Rogers and RW Houde

The relative analgesic potency of oral and intramuscular codeine was evaluated in a double-blind crossover comparison of graded single doses in patients with chronic pain due to cancer. When both duration and intensity of analgesia are considered (total effect), oral codeine was 6/10 as potent as the intramuscular form. This is a high oral/parenteral analgesic relative potency ratio compared with morphine, metopon and oxymorphone and correlates well with the results of recent studies which have determined the oral vs. intramuscular bioavailability of codeine in man. Oral and intramuscular oxycodone were also compared in a similar patient group. Like codeine, oxycodone retained at least 1/2 of its analgesic activity when administered orally. We hypothesize that the high oral/parenteral relative potency ratios of codeine and oxycodone relative to morphine and its congeners are not due to more efficient absorption after oral administration, but rather that methylation at position 3 in codeine and oxycodone protects these drugs from rapid first-pass metabolism.

Volume 207, Issue 1, pp. 92-100, 10/01/1978
Copyright © 1978 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 CROBMHome page
R. A. Dionne and C. W. Berthold
Therapeutic Uses of Non-Steroidal Anti-Inflammatory Drugs in Dentistry
Critical Reviews in Oral Biology & Medicine, January 1, 2001; 12(4): 315 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Palliat MedHome page
P. A Glare
Oxycodone - a substitute for morphine in cancer pain management?
Palliative Medicine, January 1, 1992; 6(1): 79 - 80.
[PDF]

Home page
 Palliat MedHome page
G. Hanks and P. Hoskin
Review article : Opioid analgesics in the management of pain in patients with cancer. A review
Palliative Medicine, January 1, 1987; 1(1): 1 - 25.
[PDF]

Home page
 Arch Intern MedHome page
W. T. Beaver
Aspirin and Acetaminophen as Constituents of Analgesic Combinations
Arch Intern Med, February 23, 1981; 141(3): 293 - 300.
[Abstract] [PDF]

Home page
 JAMAHome page
W. T. Beaver
Management of Cancer Pain With Parenteral Medication
JAMA, December 12, 1980; 244(23): 2653 - 2657.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1978 by the American Society for Pharmacology and Experimental Therapeutics.